Diphenhydramine Hydrochloride Oral Solution USP

Manufacturer
Redmont Pharmaceuticals, LLC
Effective date
2026-08-03
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
daily-update
Hydrated at
2026-08-04 03:37:49

Label at a glance#

ProductDiphenhydramine HCL
Active ingredientDIPHENHYDRAMINE HYDROCHLORIDE
Label structure14 sections

Indications and uses

Diphenhydramine hydrochloride in the oral form is effective for the following indications: For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been c...

Dosage and administration

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. 25 to 50 mg three or four times daily. The nighttime sleep-aid dosage is 50 mg at bedti...

Storage and handling

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing and light.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx ONLY

DESCRIPTION

DESCRIPTION SECTION

Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(diphenylmethoxy)-N,N -dimethylethylamine hydrochloride and has the molecular formula C17H21NO∙HCI (molecular weight 291.82). It occurs as a white odorless, crystalline powder and is freely soluble in water and alcohol. The structural formula is as follows:

Chemical Structure
Chemical Structure

Each 5 mL contains 12.5 mg of diphenhydramine hydrochloride and alcohol 14% for oral administration. Inactive Ingredients: Citric acid, D&C Red No. 33, FD&C Red No. 40, flavoring, purified water, sodium citrate, and sucrose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. Diphenhydramine is widely distributed throughout the body, including the CNS. Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Diphenhydramine hydrochloride in the oral form is effective for the following indications:

Antihistaminic

SPL UNCLASSIFIED SECTION

For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Motion Sickness

SPL UNCLASSIFIED SECTION

For active and prophylactic treatment of motion sickness.

Antiparkinsonism

SPL UNCLASSIFIED SECTION

For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents.

SPL UNCLASSIFIED SECTION

Nighttime Sleep-aid.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Use in Neonates or Premature Infants

SPL UNCLASSIFIED SECTION

This drug should not be used in neonates or premature infants.

Use in Nursing Mothers

SPL UNCLASSIFIED SECTION

Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Antihistamines are also contraindicated in the following conditions

SPL UNCLASSIFIED SECTION

Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

WARNINGS

WARNINGS SECTION

Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.

Use in Pediatric Patients

SPL UNCLASSIFIED SECTION

In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.

Use in the Elderly (approximately 60 years or older)

SPL UNCLASSIFIED SECTION

Antihistamines are most likely to cause dizziness, sedation, and hypotension in elderly patients.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Diphenhydramine hydrochloride has an atropine-like action and therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease including asthma.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol. Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Drug Interactions

DRUG INTERACTIONS SECTION

Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.

Pregnancy

PREGNANCY SECTION

Pregnancy Category B

SPL UNCLASSIFIED SECTION

Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pediatric Use

PEDIATRIC USE SECTION

Diphenhydramine hydrochloride should not be used in neonates and premature infants (see CONTRAINDICATIONS).

Diphenhydramine hydrochloride may diminish mental alertness, or, in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see WARNINGS and OVERDOSAGE).

See also DOSAGE AND ADMINISTRATION section.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions are underscored.

  1. General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of the mouth, nose and throat.
  2. Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles.
  3. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
  4. Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions.
  5. GI System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
  6. GU System: Urinary frequency, difficult urination, urinary retention, early menses.
  7. Respiratory System: Thickening of bronchial secretions, tightness of chest or throat and wheezing, nasal stuffiness.

To report SUSPECTED ADVERSE REACTIONS, contact Redmont Pharmaceuticals, Inc. at 1-800-986-5909 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing and gastrointestinal symptoms may also occur.

If vomiting has not occurred spontaneously, the patient should be induced to vomit. This is best done by having him drink a glass of water or milk after which he should be made to gag. Precaution against aspiration must be taken, especially in infants and children.

If vomiting is unsuccessful, gastric lavage is indicated within 3 hours after ingestion and even later if large amounts of milk or cream were given beforehand. Isotonic or 1/2 isotonic saline is the lavage solution of choice.

Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and therefore are valuable for their action in rapid dilution of bowel content.

Stimulants should not be used.

Vasopressors may be used to treat hypotension.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours.

Adults

SPL UNCLASSIFIED SECTION

25 to 50 mg three or four times daily. The nighttime sleep-aid dosage is 50 mg at bedtime.

Pediatric Patients, other than premature infants and neonates

SPL UNCLASSIFIED SECTION

12.5 to 25 mg three or four times daily. Maximum daily dosage not to exceed 300 mg. For physicians who wish to calculate the dose on the basis of body weight or surface area, the recommended dosage is 5 mg/kg/24 hours or 150 mg/m2/24 hours.

Data are not available on the use of diphenhydramine hydrochloride as a nighttime sleep-aid in children under 12 years.

The basis for determining the most effective dosage regimen will be the response of the patient to medication and the condition under treatment.

In motion sickness, full dosage is recommended for prophylactic use, the first dose to be given 30 minutes before exposure to motion and similar doses before meals and upon retiring for the duration of exposure.

STORAGE

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from freezing and light.

HOW SUPPLIED

HOW SUPPLIED SECTION

Each 5 mL of Diphenhydramine Hydrochloride Oral Solution USP (clear purple/red liquid, cinnamon/anise flavor) contains 12.5 mg diphenhydramine hydrochloride with 14% alcohol and is supplied in the following oral dosage forms:

NDC 71741-511-04: 118mL Bottle

SPL UNCLASSIFIED SECTION

Distributed by:

Redmont
Pharmaceuticals, LLC
Birmingham, AL 35209

X048904R0626 R06/26

PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 71741-511-04

Diphenhydramine
HCL

Oral Solution, USP

12.5 mg/5 mL

Each 5 mL (teaspoonful) contains:
Diphenhydramine HCl.....12.5 mg
Alcohol.......................14%

Rx Only ∙ 118 mL

REDMONT
PHARMACEUTICALS

PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label
PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71741-51171741-511-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A087513-001DIPHENHYDRAMINE HYDROCHLORIDEDIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALAARLD, RS1982-02-10

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A087513-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALAARLD, RS1982-02-1084e616aacf4f…
2026-08-18 06:07:402026-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALAARLD, RS1982-02-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-103f01610625f2…
2019-09-15 20:21 UTC2019-09A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRLD, RS1982-02-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-103bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-103a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A087513-001DIPHENHYDRAMINE HYDROCHLORIDE12.5MG/5MLELIXIR / ORALRS1982-02-10f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A087513-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A087513-001AA1caaa826d4ba7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A087513-001AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Diphenhydramine HCLDIPHENHYDRAMINE HYDROCHLORIDERedmont Pharmaceuticals, LLCd8944f3c-acef-4ebe-9633-7d641ae95edf2026-08-03Warnings, Adverse reactionsExact identifier
ndc (package): 71741-511-04
ndc (product): 71741-511
ndc11 (package): 71741051104
spl id: b70e7c6f-aaf1-40dd-8e7b-09215db5b4ac
spl set id: d8944f3c-acef-4ebe-9633-7d641ae95edf

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.